In 1999 a change in the law meant people who were not vets could own veterinary practices. A company based in Diss, Norfolk, took the opportunity and started buying small independent practices around the country. More than 25 years later that company, CVS Group, runs over 480 practices in the UK and Australia and employs about 9,000 people, including roughly 2,500 vets and 3,300 nurses. It moved from AIM to the London Stock Exchange's Main Market in January 2026 and joined the FTSE 250.
CVS (LSE:CVSG) grew by repeating one approach: buy local practices, keep their local identity, and add group-wide purchasing, diagnostics, online retail and a pet health subscription scheme. Simon Innis, chief executive from 2004, oversaw most of the UK roll-up. Richard Fairman, chief executive since 2019, has focused on margins, Capital discipline and expansion in Australia.
Consolidation drew scrutiny. The Competition and Markets Authority (CMA) halted a planned deal for rival The Vet in 2022, then spent more than two years investigating the UK vet market. With that investigation concluded, a new chief executive being sought and full-year results due on 24 September 2026, investors are weighing what comes next.
How the Business makes money
Almost all of CVS's Revenue comes from its veterinary practices, mostly small-animal clinics plus some equine, farm and referral centres. In the year to 30 June 2025 the practices division brought in £616.1m of the group's £673.2m continuing revenue. Laboratories, which serves the group's practices and outside customers, made £31.4m, and Animed Direct, the online pharmacy, made £45.9m. (Divisional figures include inter-division sales, so they exceed the group total.)
The Healthy Pet Club provides steady income: owners pay monthly for preventive care, and membership reached 519,000 at June 2025, up 3.2%. The crematoria division was sold in May 2025 for initial proceeds of £42.3m, about 10 times its adjusted EBITDA according to CVS, with the cash going towards Australia.
Recent performance
FY25 was a quieter year. Like-for-like (LFL) sales rose only 0.2% as the UK market weakened. Adjusted EBITDA still grew 9.4% to £134.6m, a 20.0% margin. Adjusted EPS fell 3.8% to 80.1p and the final Dividend went up to 8.5p. Net Debt fell to £129.1m, or 1.18 times EBITDA.
Trading has picked up since then. In the six months to 31 December 2025, revenue grew 5.8% to £356.9m and LFL sales rose 2.7%. Gross Margin improved to 44.2% from 42.6%, adjusted pre-tax profit rose 8.0% to £40.3m and adjusted EPS rose 5.8% to 40.2p. Statutory pre-tax profit, however, dipped to £15.2m, which shows how large the adjusting items are.
The 23 July 2026 trading update covered the year to 30 June 2026. Revenue was £712.8m, up 5.9%. LFL growth was 2.1% and adjusted EBITDA was about £141.5m, in line with the range of analyst forecasts the company quoted (£140.4m–£142.3m). The margin held at 19.9%. Net bank borrowings rose to £199.6m, or about 1.63 times EBITDA, reflecting acquisitions and buybacks.
Strategy and catalysts
Australia is now the main focus for acquisitions. Australian revenue rose by £27.0m to £79.1m in FY26: about 11% of group revenue but around 16% of EBITDA before central costs, which points to higher margins. During the year CVS bought six practices (14 sites) for A$91.0m and bought out a minority stake, and it now has 35 practices across 57 sites there. Management plans to spend around £50m a year on Australian deals.
Regulation is clearer than it was. On 24 March 2026 the CMA's final decision set out several remedies: a price cap on prescriptions (£21 including VAT for the first drug and £12.50 for each extra drug prescribed at the same time), published price lists, clearer group branding and new complaints procedures. CVS said it disagreed with parts of the package but could live with it. It has already published price lists and applied joint branding at more than 80% of its UK companion animal practices. A Final Order is expected later in 2026. UK acquisitions were paused during the investigation.
Capital returns and funding. In May 2026 CVS agreed a new £350m bank Facility running to 2030, at a lower interest margin. It also launched a £50m share buyback, due to finish by November 2026, after a £20m programme earlier in the year. By 18 September 2026 it had bought back about 2.55m shares at an average of 1,256.3p.
Leadership. On 30 March 2026 Richard Fairman said he would retire, for personal reasons, once a successor is appointed.
Valuation talking points
Recent buyback purchases have been at around 1,270p–1,325p. With roughly 67.6m shares in issue, that implies a Market Value of about £880m. Adding net bank borrowings gives a rough Enterprise value of 7–8 times FY26 adjusted EBITDA, and the shares trade at roughly 16 times FY25 adjusted EPS. The dividend is small, as cash goes mainly into acquisitions, capital spending (about £30m a year from now on) and buybacks.
The bull case
- Like-for-like growth has returned to around 2–3%, and margins have held steady despite a weak UK consumer backdrop.
- Australia offers a long runway of acquisitions at attractive margins, and that business has grown quickly.
- The CMA's final decision removes more than two years of uncertainty, and CVS appears to have been well prepared for the remedies.
- Borrowing is below the group's 2.0x ceiling, which leaves room for both deals and buybacks.
The bear case
- The prescription price cap and price transparency rules could hold back UK pricing and pharmacy income over time.
- The gap between adjusted and statutory profit is large and needs close watching.
- The chief executive who led the Australia strategy and the CMA response is leaving, and no successor has been named yet.
- Debt has risen from 1.18x to around 1.63x, and buying overseas brings currency, integration and execution risk.
- The shortage of vets and pressure on wages remain a constraint across the industry.
The bottom line
CVS became one of the UK's largest vet groups by patiently buying local practices and adding profitable extras: laboratories, online retail and Healthy Pet Club subscriptions. With the UK market more mature and more closely regulated, growth now depends on Australia, organic improvement and returning cash.
The results on 24 September 2026 and the choice of the next chief executive will test this model. The key questions are how the CMA remedies affect UK earnings, and whether Australia can make up for slower acquisition-led growth at home.






Please wait processing your request...